At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
A006 DPI +4 moredrug
Likely dose
A006 DPI 110 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy, Dose-ranging and Safety Evaluation (A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Single Dose, Five-arm, Crossover, and Dose-ranging Study of A006 in Adult Asthma Patients)
In Brief
A Phase 2 clinical trial evaluating A006 DPI, Placebo DPI, and 1 other intervention for Asthma. Completed, enrolled 22 participants across 4 sites.
Detailed Summary
This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose inhaler (MDI) Active Control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedAug 2014
Primary CompletionSep 2014
Study CompletionOct 2014
TodayJul 2026
First PostedAug 7, 2014
Enrollment StartJul 1, 2014
Primary CompletionSep 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.9 years ago
Interventions
A006 DPIdrug
Single dose 110 mcg, 1 inhalation
A006 DPIdrug
Single dose 220 mcg, 1 inhalation
Placebo DPIother
Placebo, 1 inhalation
Proventil® MDIdrug
Single dose 90 mcg, 1 inhalation
Proventil® MDIdrug
Single dose 90 mcg, 2 inhalations